atpγs

ATPγS tetralithium salt is a good substrate for RNA-stimulated nucleotide hydrolysis and RNA unwinding activity of eIF4A.

ATP-γ-S tetrasodium (Adenosine-5'-O-(3-thiotriphosphate) tetrasodium) is a purinergic P2Y11 receptor agonist and ATP analog that induces inositol phosphate accumulation, induces insulin secretion from MIN6 pancreatic islet β-cells, and induces an increase in intracellular calcium concentration. ATP-γ-S tetrasodium inhibits the induction of the Junin virus. Junin virus-induced increase in the level of mRNA encoding bone morphogenetic protein 6 (BMP6) reduces particle-forming units (PFUs) in Junin virus-infected primary rat osteoblasts.

Aprikalim (RP 52891) is an adenosine triphosphate potassium channel (KATP) opener that protects against nerve damage in a rabbit model of spinal cord ischemia.Aprikalim inhibits vasoconstriction and inhibits the elevation of [Ca2+]i during myocardial paralysis, and can be used to study cardiovascular disease.

Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment.

Amiodarone hydrochloride is an anti-anginal agent and a class III antiarrhythmic drug that inhibits potassium channels (including wild-type hERG channels and their tail currents, with an IC₅₀ of approximately 45 nM) as well as voltage-gated sodium channels. This leads to prolonged action potential duration in ventricular and atrial myocytes, resulting in reduced heart rate and vascular resistance. It activates ERK1/2 and p38 MAPK signaling pathways in fibroblasts, promoting cell proliferation and myofibroblast differentiation. Amiodarone hydrochloride is widely used in the study of supraventricular and ventricular arrhythmias and can also be used to establish pulmonary fibrosis animal models.

Glipizide (CP 28720) is a short-acting, second-generation sulfonylurea with hypoglycemic activity.

Glibenclamide (Glyburide) is an antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.

D-α-Hydroxyglutaric acid disodium [Disodium (R)-2-Hydroxyglutarate] is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with a Ki of 0.628 mM.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family.

Hydroxyhexamide ((±)-Hydroxyhexamid) is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent.

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

Gboxin is an inhibitor of oxidative phosphorylation that targets glioblastoma,inhibits the activity of F0F1 ATP synthase, with antitumour activity.

Glibornuride, a blocker of ATP-sensitive K+ channels (pKi: 5.75), inhibits high-affinity [3H]-glibenclamide binding with potencies corresponding to its K+ channel activity.

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).

ATP synthase inhibitor3 (compound PT6) is an orally active inhibitor targeting the F-ATP synthase of Mycobacterium tuberculosis (IC50=0.788 μM). It effectively inhibits the growth of the Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro, depleting intracellular ATP levels at an IC50 of 30 μM.

2'-Deoxytubercidin 5'-triphosphate (C7dATP) sodium is a deoxyadenosine triphosphate (dATP) analog designed to reduce electrophoretic mobility anomalies caused by compression at G or A residues, thereby enhancing the quality of DNA sequencing data.

ATP Synthesis-IN-3 (compound 31) is an inhibitor of ATP hydrolysis that provides a protective effect during myocardial ischemia. It increases ATP levels in ischemic myocardial cells, enhances the phosphorylation of PKA and substrate proteins, and inhibits ischemia-induced apoptosis (cell apoptosis).

2-NH2-PuTP (n2h6ATP) sodium, an ATP analog, serves as a competitive inhibitor of pyruvate-stimulated adenylate cyclase with a Ki of 1.7 mM.

5-Hydroxydecanoic acid is a selective ATP-sensitive K+ (KATP) channel blocker (IC50 of ~30 μM). 5-Hydroxydecanoic acid is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity.

5-Hydroxydecanoate sodium is a selective ATP-sensitive K+ (KATP) channel blocker with an IC50 of approximately 30 μM and a substrate for mitochondrial outer membrane acyl-CoA synthetase, possessing antioxidant properties.

TH5427 is a lead NUDT5 inhibitor(MG assay IC50 = 29 nM).

Mtb ATP synthase-IN-1 (compound 6ab) is a potent inhibitor of Mycobacterium tuberculosis (Mtb) ATP synthase (MIC = 0.452-0.499 μg/mL) [1] that can be used in anti-mycobacterium research, showing low cytotoxicity (Vero IC 50 > 64 μg/mL) and acceptable oral bioavailability with good metabolic stability.